Similar articles

• Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.

  Inoh K, Muramatsu H, Torii S, Ikematsu S, Oda M, Kumai H, Sakuma S, Inui T, Kimura T, Muramatsu T. Inoh K, et al. Jpn J Clin Oncol. 2006 Apr;36(4):207-11. doi: 10.1093/jjco/hyl004. Epub 2006 Apr 12. Jpn J Clin Oncol. 2006. PMID: 16611663
• Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.

  Smyth MJ, Pietersz GA, Farquhar I, McKenzie C. Smyth MJ, et al. Targeted Diagn Ther. 1988;1:123-56. Targeted Diagn Ther. 1988. PMID: 2979055 Review. No abstract available.
• KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.

  Bumol TF, Baker AL, Andrews EL, DeHerdt SV, Briggs SL, Spearman ME, Apelgren LD. Bumol TF, et al. Targeted Diagn Ther. 1988;1:55-79. Targeted Diagn Ther. 1988. PMID: 2979063 Review. No abstract available.
• The effect of bispecific monoclonal antibody recognizing both hepatoma-specific membrane glycoprotein and anthracycline drugs on the metastatic growth of hepatoma AH66.

  Tsukada Y, Ohkawa K, Hibi N, Tsuzuki K, Oguma K, Satoh H. Tsukada Y, et al. Cancer Biochem Biophys. 1989 May;10(3):247-56. Cancer Biochem Biophys. 1989. PMID: 2789098
• Investigations with monoclonal antibody drug (anthracycline) conjugates.

  Hermentin P, Seiler FR. Hermentin P, et al. Behring Inst Mitt. 1988 Apr;(82):197-215. Behring Inst Mitt. 1988. PMID: 3044339 Review.